Research & Development

What Are the Key Drivers and Challenges in Pancreatic Cancer Growth?
Research & Development What Are the Key Drivers and Challenges in Pancreatic Cancer Growth?

Pancreatic cancer is a complex and aggressive disease that remains one of the deadliest forms of cancer. Its market, valued at approximately USD 1.6 billion in 2020 across the 7MM regions (the United States, the EU-4 [Italy, Spain, France, and Germany], the United Kingdom, and Japan), is poised for

Is HilleVax's Norovirus Vaccine Viable for Adult Populations?
Research & Development Is HilleVax's Norovirus Vaccine Viable for Adult Populations?

HilleVax, a biotechnological firm previously in the spotlight for its experimental Norovirus vaccine, HIL-214, has made headlines again. After an extensive and ultimately disappointing Phase 2b trial in infants, the company is now strategizing a new target demographic: adults. Given the intricate

Immix Biopharma Begins U.S. Dosing in NXC-201 AL Amyloidosis CAR-T Trial
Research & Development Immix Biopharma Begins U.S. Dosing in NXC-201 AL Amyloidosis CAR-T Trial

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, has reached a pivotal milestone by dosing its first patient in the U.S. for the NEXICART-2 clinical trial. This significant achievement aims to treat relapsed/refractory AL Amyloidosis using CAR-T cell therapy, known as NXC-201.

How Will IASO Bio and Innovent's Collaboration Impact CAR-T Therapy?
Research & Development How Will IASO Bio and Innovent's Collaboration Impact CAR-T Therapy?

The biopharmaceutical industry is witnessing major advancements in cell therapy, with CAR-T therapies surfacing as a pioneering avenue for treating complex diseases. The latest development in this field is the expanded strategic collaboration between IASO Biotechnology (IASO Bio) and Innovent

How is Clinical Trial Outsourcing Transforming Drug Development?
Research & Development How is Clinical Trial Outsourcing Transforming Drug Development?

Clinical trial outsourcing has fundamentally transformed the landscape of drug development, allowing pharmaceutical companies to streamline operations, reduce costs, and accelerate the path to market. This paradigm shift is driven by several converging factors, including the rapid growth in

Emerging Innovations Propel CAR-T Therapy to 2033 Market Expansion
Research & Development Emerging Innovations Propel CAR-T Therapy to 2033 Market Expansion

The landscape of Chimeric Antigen Receptor T-cell (CAR-T) therapies is witnessing rapid evolution as emerging companies introduce innovative solutions to overcome existing challenges. These therapies, which involve genetically engineering a patient’s T cells to target cancer cells, have shown i

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later